| scholarly article | Q13442814 |
| P50 | author | Peter J. Snyder | Q46519599 |
| Brian R Ott | Q105998912 | ||
| P2093 | author name string | M A Pelosi | |
| G Tremont | |||
| P2860 | cites work | Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q24595802 |
| The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29614406 | ||
| Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible | Q33773031 | ||
| Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments | Q34039983 | ||
| Community engagement in diverse populations for Alzheimer disease prevention trials. | Q34071045 | ||
| Public beliefs and knowledge about risk and protective factors for Alzheimer's disease | Q34177996 | ||
| Should we disclose amyloid imaging results to cognitively normal individuals? | Q34286140 | ||
| Public perceptions of presymptomatic testing for Alzheimer disease | Q35206422 | ||
| Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants | Q35595661 | ||
| A model for the design and implementation of a participant recruitment registry for clinical studies of older adults | Q35886046 | ||
| Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment | Q36609607 | ||
| Using AD biomarker research results for clinical care: a survey of ADNI investigators | Q37227059 | ||
| The impact of the availability of prevention studies on the desire to undergo predictive testing in persons at risk for autosomal dominant Alzheimer's disease. | Q37380826 | ||
| Disclosure of APOE genotype for risk of Alzheimer's disease | Q37423417 | ||
| Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease | Q37690501 | ||
| The ethics of disclosing genetic diagnosis for Alzheimer's disease: do we need a new paradigm? | Q37889522 | ||
| Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability. | Q38691914 | ||
| Prediction of Cognitive and Functional Decline Using the Telephone-Administered Minnesota Cognitive Acuity Screen. | Q38892045 | ||
| Anticipating response to predictive genetic testing for Alzheimer's disease: a survey of first-degree relatives | Q40770742 | ||
| Patient and carer views on participating in clinical trials for prodromal Alzheimer's disease and mild cognitive impairment | Q43604874 | ||
| Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease | Q44470398 | ||
| Alzheimer disease and pre-emptive suicide | Q46053421 | ||
| Public attitudes about genetic testing for Alzheimer's disease | Q48664461 | ||
| Use of the telephone-administered Minnesota Cognitive Acuity Screen to detect mild cognitive impairment. | Q50980473 | ||
| Development and standardization of a new telephonic cognitive screening test: the Minnesota Cognitive Acuity Screen (MCAS). | Q51643696 | ||
| Predicting functional impairments in cognitively impaired older adults using the Minnesota Cognitive Acuity Screen | Q85505331 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 23-29 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Alzheimer's & dementia (New York, N. Y.) | Q27726239 |
| P1476 | title | A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure | |
| P478 | volume | 2 |
| Q56373543 | Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure |
| Q89695879 | Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results |
| Q47742387 | Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults |
| Q57174282 | Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review |
| Q90273183 | Experiences of dementia and attitude towards prevention: a qualitative study among older adults participating in a prevention trial |
| Q50421914 | Perspectives on Communicating Biomarker-Based Assessments of Alzheimer's Disease to Cognitively Healthy Individuals. |
| Q38821788 | Recruiting to preclinical Alzheimer's disease clinical trials through registries. |
| Q47953945 | Safety of disclosing amyloid status in cognitively normal older adults |
| Q46028917 | Study partners should be required in preclinical Alzheimer's disease trials. |
Search more.